NEW YORK (GenomeWeb News) – Response Genetics today announced the execution of a provider contract with Blue Cross and Blue Shield of Illinois, providing the health plan's 7.4 million members coverage for the Los Angeles-based molecular diagnostics firm's tests.

Response Genetics offers molecular predictive tests for lung, colon, gastric, and melanoma cancers, as well as tests for detecting EGFR, KRAS, and other mutations. Its tests, the firm said, help physicians determine which treatments may be best for each individual patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.